대한간호학회지 (Journal of Korean Academy of Nursing)

한국간호과학회 (Korean Society of Nursing Science)
권호 표지
DOI QR코드

DOI QR Code

Reliability and Validity of the Korean Version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire to Assess Chemotherapy-induced Peripheral Neuropathy

  • Kim, Hye Young (College of Nursing, Chonbuk National University) ;
  • Kang, Jeong Hee (College of Nursing, Chonbuk National University) ;
  • Youn, Hyun Jo (Department of Surgery, Chonbuk National University Medical School) ;
  • So, Hyang Sook (College of Nursing, Chonnam National University) ;
  • Song, Chi Eun (Department of Hematology, Chonnam National University Hwasun Hospital) ;
  • Chae, Seo Young (Department of Oncology, Chonnam National University Hwasun Hospital) ;
  • Jung, Sung Hoo (Department of Surgery, Chonbuk National University Medical School) ;
  • Kim, Sung Reul (College of Nursing, Chonbuk National University) ;
  • Kim, Ji Young (College of Nursing, Chonbuk National University)
  • 투고 : 2014.07.14
  • 심사 : 2014.10.14
  • 발행 : 2014.12.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Purpose: This study was performed to assess the reliability and validity of the Korean version of European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Chemotherapy-induced peripheral neuropathy 20 items (EORTC QLQ-CIPN20) in patients receiving neurotoxic chemotherapy. Methods: A convenience sample of 249 Korean cancer patients, previously or currently, being treated with peripheral neurotoxic chemotherapeutic agents were asked to fill in the questionnaire. Collected data were analyzed using SPSS 21.0 and AMOS 21.0. Construct validity, known-group validity, concurrent validity, and internal consistency reliability of the Korean version of the QLQ-CIPN20 were evaluated. Results: Factor analysis confirmed 3 dimensions of CIPN: sensory, motor, and autonomic. The factor loadings of the 20 items on the 3 subscales ranged from .38 to .85. The 3 subscale-model was validated by confirmatory factor analysis (GFI=.90, AGFI=.86, RMSR=.05, NFI=.87, and CFI=.94), and concurrent validity was demonstrated with the EORTC QLQ-C30. Furthermore, the QLQ-CIPN20 established known-group validity. The Cronbach's alpha coefficients for internal consistency of the subscales ranged from .73 to .89. Conclusion: The Korean version of the EORTC QLQ-CIPN20 showed satisfactory construct, concurrent, and known-group validity, as well as internal reliability.

키워드

참고문헌

  1. Azhary H, Farooq MU, Bhanushali M, Majid A, Kassab MY. Peripheral neuropathy: Differential diagnosis and management. American Family Physician. 2010;81(7):887-892.
  2. Postma TJ, Aaronson NK, Heimans JJ, Muller MJ, Hildebrand JG, Delattre JY, et al. The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: The QLQ-CIPN20. European Journal of Cancer. 2005;41(8):1135-1139. http://dx.doi.org/10.1016/j.ejca.2005.02.012
  3. Dunlap B, Paice JA. Chemotherapy-induced peripheral neuropathy: A need for standardization in measurement. The Journal of Supportive Oncology. 2006;4(8):398-399.
  4. Delforge M, Blade J, Dimopoulos MA, Facon T, Kropff M, Ludwig H, et al. Treatment-related peripheral neuropathy in multiple myeloma: The challenge continues. Lancet Oncology. 2010;11(11):1086-1095. http://dx.doi.org/10.1016/s1470-2045(10)70068-1
  5. Kautio AL, Haanpaa M, Kautiainen H, Kalso E, Saarto T. Burden of chemotherapy-induced neuropathy-a cross-sectional study. Supportive Care in Cancer. 2011;19(12):1991-1996. http://dx.doi.org/10.1007/s00520-010-1043-2
  6. Kiser DW, Greer TB, Wilmoth MC, Dmochowski J, Naumann RW. Peripheral neuropathy in patients with gynecologic cancer receiving chemotherapy: Patient reports and provider assessments. Oncology Nursing Forum. 2010;37(6):758-764. http://dx.doi.org/10.1188/10.onf.758-764
  7. Tofthagen C, McAllister RD, McMillan SC. Peripheral neuropathy in patients with colorectal cancer receiving oxaliplatin. Clinical Journal of Oncology Nursing. 2011;15(2):182-188. http://dx.doi.org/10.1188/11.cjon.182-188
  8. Visovsky C, Collins M, Abbott L, Aschenbrenner J, Hart C. Putting evidence into practice: Evidence-based interventions for chemotherapy-induced peripheral neuropathy. Clinical Journal of Oncology Nursing. 2007;11(6):901-913. http://dx.doi.org/10.1188/07.cjon.901-913
  9. Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. Journal of Clinical Oncology. 2006;24(19):3113-3120. http://dx.doi.org/10.1200/jco.2005.04.7779
  10. Griffith KA, Merkies IS, Hill EE, Cornblath DR. Measures of chemotherapy-induced peripheral neuropathy: A systematic review of psychometric properties. Journal of the Peripheral Nervous System. 2010;15(4):314-325. http://dx.doi.org/10.1111/j.1529-8027.2010.00292.x
  11. Postma TJ, Heimans JJ. Grading of chemotherapy-induced peripheral neuropathy. Annals of Oncology. 2000;11(5):509-513. https://doi.org/10.1023/A:1008345613594
  12. Wickham R. Chemotherapy-induced peripheral neuropathy: A review and implications for oncology nursing practice. Clinical Journal of Oncology Nursing. 2007;11(3):361-376. http://dx.doi.org/10.1188/07.cjon.361-376
  13. Cavaletti G, Cornblath DR, Merkies IS, Postma TJ, Rossi E, Frigeni B, et al. The chemotherapy-induced peripheral neuropathy outcome measures standardization study: From consensus to the first validity and reliability findings. Annals of Oncology. 2013;24(2):454-462. http://dx.doi.org/10.1093/annonc/mds329
  14. Barton DL, Wos EJ, Qin R, Mattar BI, Green NB, Lanier KS, et al. A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA. Supportive Care in Cancer. 2011;19(6):833-841. http://dx.doi.org/10.1007/s00520-010-0911-0
  15. Kim HY, Kang JH, Song CE, Youn HJ. Chemotherapy-induced peripheral neuropathy and quality of life in breast cancer patients. Asian Oncology Nursing. 2013;13(4):222-230. http://dx.doi.org/10.5388/aon.2013.13.4.222
  16. Mols F, Beijers T, Lemmens V, van den Hurk CJ, Vreugdenhil G, van de Poll-Franse LV. Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry. Journal of Clinical Oncology. 2013;31(21):2699-2707. http://dx.doi.org/10.1200/jco.2013.49.1514
  17. Kim JH, Choi KS, Kim TW, Hong YS. Quality of life in colorectal cancer patients with chemotherapy-induced peripheral neuropathy. Journal of Korean Oncology Nursing. 2011;11(3):254-262. http://dx.doi.org/10.5388/jkon.2011.11.3.254
  18. Kwak MK, Kim EJ, Lee ER, Kwon IG, Hwang MS. Characteristics and quality of life in patients with chemotherapy-induced peripheral neuropathy. Journal of Korean Oncology Nursing. 2010;10(2):231-239. http://dx.doi.org/10.5388/jkon.2010.10.2.231
  19. Dewolf L, Koller M, Velikova G, Johnson C, Scott N, Bottomley A. EORTC quality of life group translation procedure. 3rd ed. Brussels, BE: EORTC Quality of Life Group; 2009.
  20. Tabachnick BG, Fidell LS. Using multivariate statistics. 3rd ed. New York, NY: Harper Collins Publishers; 1996.
  21. Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A. The EORTC QLQ-C30 scoring manual. 3rd ed. Brussels, BE: EORTC Quality of Life Group; 2001.
  22. Yun YH, Park YS, Lee ES, Bang SM, Heo DS, Park SY, et al. Validation of the Korean version of the EORTC QLQ-C30. Quality of Life Research. 2004;13(4):863-868. https://doi.org/10.1023/B:QURE.0000021692.81214.70
  23. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute. 1993;85(5):365-376. https://doi.org/10.1093/jnci/85.5.365
  24. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the eastern cooperative oncology group. American Journal of Clinical Oncology. 1982;5(6):649-655. https://doi.org/10.1097/00000421-198212000-00014
  25. Kim GS. Analysis structural equation modeling. Seoul: Hannarae Publishing Co.; 2007.
  26. Nunnally JC, Bernstein IH. Psychometric theory. 3rd ed. New York, NY: McGraw-Hill; 1994.
  27. Kim EJ. Accessing factor structure and construct validity of the successful aging inventory. Journal of Korean Academy of Nursing. 2013;43(4):568-578. http://dx.doi.org/10.4040/jkan.2013.43.4.568
  28. Park HA. Problems and issues in developing measurement scales in nursing. Journal of Nursing Query. 2005;14(1):46-72.
  29. Kim SH, Jo MW, Lee SI. Psychometric properties of the Korean short form-36 health survey version 2 for assessing the general population. Asian Nursing Research. 2013;7(2):61-66. https://doi.org/10.1016/j.anr.2013.03.001
  30. Lee EH, Moon S, Cho SY, Oh YT, Chun M, Kim SH, et al. Psychometric evaluation of a need scale for cancer patients undergoing follow-up care. Journal of Korean Academy of Nursing. 2010;40(4):551-560. http://dx.doi.org/10.4040/jkan.2010.40.4.551

피인용 문헌

  1. Relationship between Chemotherapy-induced Peripheral Neuropathy and Quality of Life in Patients with Hematologic Malignancies vol.27, pp.3, 2014, https://doi.org/10.7475/kjan.2015.27.3.358
  2. Psychometric Properties of Turkish Version of the Dutch Objective Burden Inventory vol.9, pp.3, 2015, https://doi.org/10.1016/j.anr.2015.07.001
  3. Oxaliplatin-Induced Peripheral Neuropathy and Quality of Life in Patients with Digestive System Cancer vol.28, pp.3, 2014, https://doi.org/10.7475/kjan.2016.28.3.343
  4. 항암제 유발 말초신경병증 변증평가도구의 신뢰도 및 타당도 평가 vol.37, pp.4, 2016, https://doi.org/10.22246/jikm.2016.37.4.631
  5. 항암제 유발 말초신경병증환자와 유기산검사 마커와의 상관성 연구 vol.38, pp.1, 2014, https://doi.org/10.13048/jkm.17007
  6. A Prospective Study of Chronic Oxaliplatin-Induced Neuropathy in Patients with Colon Cancer: Long-Term Outcomes and Predictors of Severe Oxaliplatin-Induced Neuropathy vol.14, pp.1, 2018, https://doi.org/10.3988/jcn.2018.14.1.81
  7. The evaluation of changes in peripheral neuropathy and quality-of-life using low-frequency electrostimulation in patients treated with chemotherapy for breast cancer: a study protocol vol.19, pp.1, 2014, https://doi.org/10.1186/s13063-018-2874-2
  8. Rasch model-based testing of the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy (QLQ-CIPN20) using Alliance vol.27, pp.7, 2014, https://doi.org/10.1007/s00520-018-4553-y
  9. A Randomized, Placebo-Controlled Trial Evaluating Changes in Peripheral Neuropathy and Quality of Life by Using Low-Frequency Electrostimulation on Breast Cancer Patients Treated With Chemotherapy vol.19, pp.None, 2020, https://doi.org/10.1177/1534735420925519
  10. Efficacy and safety of intravenous administration of high-dose selenium for preventing chemotherapy-induced peripheral neuropathy in platinum-sensitive recurrent ovarian, fallopian or primary peritone vol.32, pp.5, 2021, https://doi.org/10.3802/jgo.2021.32.e73
  11. Psychometric evaluation of the Arabic Version the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Chemotherapy-Induced Peripheral Neuropathy Questionnaire vol.28, pp.5, 2021, https://doi.org/10.1080/23279095.2019.1677232